Adsorption of inflammatory cytokines using a heparin-coated extracorporeal circuit.

Cardiopulmonary bypass (CPB) surgeries cause an increase in plasma inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) along with whole-body inflammatory responses. The inflammatory responses during a CPB treatment are reduced when using a heparin-coated extracorporeal circuit. Because many cytokines, growth factors, and complements are known to interact with heparin, the reduction of inflammatory responses by a heparin-coated circuit is likely to depend on this heparin-binding nature of the inflammatory cytokines. In this study, the inflammatory cytokines, TNF-alpha and IL-6, in fetal bovine serum (FBS) bound to a heparin-agarose beads (heparin beads)-column and the adsorptions were competitively inhibited on addition of heparin in a concentration-dependent manner. TNF-alpha in FBS required a higher concentration of heparin (50% concentration inhibition [IC50] > 20microg/ml) to inhibit adsorption to the heparin beads-column compared with IL-6, probably because of a stronger interaction between TNF-alpha and heparin-beads. TNF-alpha and IL-6 concentrations in human heparinized blood significantly increased after a CPB treatment. Although the adsorbed amount of IL-6 onto the heparin-coated circuit was low (less than 6% of free circulating IL-6), a significant amount of TNF-alpha adsorbed onto the circuit (23.9-755% of free circulating TNF-alpha). Therefore, the adsorption of inflammatory cytokines, especially TNF-alpha, onto the inner heparin-coated surface of an extracorporeal circuit may partly account for a reduction in inflammatory responses.

[1]  R. Mummery,et al.  Characterization of the Heparin-Binding Properties of IL-61 , 2000, The Journal of Immunology.

[2]  Y. Shimazaki,et al.  Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids. , 1999, Artificial organs.

[3]  C. Baufreton,et al.  Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits , 1998, Perfusion.

[4]  R. Rodby.  Hemofiltration for SIRS: bloodletting, twentieth century style? , 1998, Critical care medicine.

[5]  John P. Johnson,et al.  Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. , 1998, Critical care medicine.

[6]  Yoshiya Tanaka,et al.  Chemokine and Cellular Adhesion in the Context of Heparan Sulfate Proteoglycan , 1998 .

[7]  K. Ono,et al.  Structure and Function of Heparin and Heparan Sulfate; Heparinoid Library and Modification of FGF-Activities , 1998 .

[8]  K. Watterson,et al.  Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators. , 1997, The Annals of thoracic surgery.

[9]  C. Hack,et al.  Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. , 1997, The Journal of thoracic and cardiovascular surgery.

[10]  P. Vouhé,et al.  High-volume, Zero-balanced Hemofiltration to Reduce Delayed Inflammatory Response to Cardiopulmonary Bypass in Children , 1996, Anesthesiology.

[11]  I. Jenkins,et al.  The combination of mannitol and albumin in the priming solution reduces positive intraoperative fluid balance during cardiopulmonary bypass , 1995, Perfusion.

[12]  D. Spillmann,et al.  More to "heparin" than anticoagulation. , 1994, Thrombosis research.

[13]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[14]  S Westaby,et al.  Inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[15]  E. Nilsson,et al.  On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. , 1991, The Journal of clinical investigation.

[16]  L. Hsu.  Principles of heparin-coating techniques , 1991 .

[17]  L. Kjellén,et al.  Proteoglycans: structures and interactions. , 1991, Annual review of biochemistry.